NEWS & EVENTS

Catalent and MaSTherCell Global, Inc. today announced that Catalent has agreed to acquire MaSTherCell Global, a company backed by Great Point Partners, SFPI-FPIM, and Orgenesis Inc. for an aggregate of $315 million in cash.

Catalent today announced the appointment of Ricci Whitlow as President, Clinical Supply Services. Ms. Whitlow succeeds Paul Hegwood, who plans to retire in March 2020.

Catalent today welcomed the news that DiaMedica Therapeutics has received U.S. FDA approval to commence Phase 2 clinical trials of its lead candidate, DM199, for chronic kidney disease.

Catalent today announced that Christopher Hepler, Manager, Catalent Biologics Analytical Development, has been invited to speak on ways to improve assay development at the upcoming CASSS WCBP symposium, which will be held on Jan 28 – 30, 2020.

Catalent today announced the appointment of Karen Flynn as President of Biologics and Chief Commercial Officer. Ms. Flynn has also joined the company’s Executive Leadership Team and will report to Alessandro Maselli, Catalent’s President and Chief Operating Officer.

Catalent, a global leader in clinical supply services, today announced the launch of FlexDirect™, a new direct-to-patient service for clinical trials.

Catalent today announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

Catalent today announced it will host a workshop for drug development consultants titled, “How to Effectively Work with a Development Partner – From a Consultant Standpoint”, at its facility in San Diego, on Jan. 8, 2020.

Catalent today announced the launch of its new CTSuccess™ clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.